High In Vitro Susceptibility to the First-in-Class Spiropyrimidinetrione Zoliflodacin among Consecutive Clinical Neisseria gonorrhoeae Isolates from Thailand and South Africa

Abstract excerpt

: 0.125 μg/ml), with no cross-resistance to any of the seven comparator antimicrobials. Our data support the initiation of the global zoliflodacin phase 3 randomized controlled clinical trial for uncomplicated gonorrhea.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bacterial Infections and Vaccines
• Share to Reproductive Health and Contraception
• Share to Reproductive tract infections research